Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10714892.6Aexternal-prioritypatent/EP2424864B1/en
Application filed by Glaxo Group LimitedfiledCriticalGlaxo Group Limited
Publication of CY1115992T1publicationCriticalpatent/CY1115992T1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Plural Heterocyclic Compounds
(AREA)
Abstract
Η εφεύρεση κατευθύνεται σε ορισμένες νέες ενώσεις. Ειδικώς, η εφεύρεση κατευθύνεται σε ενώσεις του τύπου (I): και άλατα αυτών. Οι ενώσεις της εφεύρεσης είναι αναστολείς δραστικότητας κινάσης, ιδιαιτέρως δραστικότητας ΡΙ3-κινάσης.The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I): and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular PI3-kinase activity.
CY20151100144T2009-04-302015-02-12
OXAZOL Substituted Indazoles as R3-Kinase Suspensions
CY1115992T1
(en)
POLYMORPHIC FORMS AND SALTS 6- (1H-INDOL-4-YL) -4- (5 - {[4- (1-METHYLETHYL) -1-PIPERAZINYL] METHYL} -1,3-OXAZOL-1-Y -INDAZOLIE AS RI3K INHIBITORS FOR USE IN THERAPY BC RESPIRATORY DISORDERS